News

Precision-Driven Flow Cytometry: Advanced Technologies Ensuring Reliable Data for Complex Therapies. All flow cytometry assays performed in C3i are qualified and/or validated. Depending on the assays, three instruments are currently used: FACS Lyric, FACS Canto, or Accellix. During the qualification/validation, accuracy is verified using a known control (where reference values have already been established). Reproducibility […]

C3i is pleased to announce the promotion of Julie Artigalas to the position of Senior Manager – Client Accounts. This promotion marks a key milestone in our ongoing commitment to delivering strategic support and high-quality service to our partners, and reflects the significant impact Julie has had on the management of our clinical projects. Holding […]

C3i announces that it has obtained regulatory approval from the EMA (European Medicine Agency) to produce cell therapy treatments for the European market. The company received a certificate of Good Manufacturing Practice (GMP) compliance following an inspection of their Montreal facility by the European Medicines Agency. Therefore, C3i obtains a certificate of GMP (Good Manufacturing […]

As a key event in the biotech industry, ATW 2025 gathered 2,500 attendees, 100 investors, 600 biotech companies, and 180 exhibitors at the Kay Bailey Hutchinson Convention Center. With six content tracks and 250 expert speakers, the event fostered innovation, regulatory discussions, and strategic collaborations to advance the future of cell and gene therapies. This […]

C3i is pleased to announce Jamie Sharp’s promotion to Associate Director of Business Development. This milestone marks a key step in our growth strategy and reflects Jamie’s significant impact on our company’s development. Jamie Sharp is a biotechnology and cell and gene therapy specialist for CDMOs. Holding a Ph.D. with a background in chemical engineering […]

This fall has brought a new dynamic to C3i with the appointment of our new CEO, Yvan Côté. His expertise and leadership reinforce our commitment to elevating C3i to new heights. With a background in biotechnology and cell biology, combined with his strong business development expertise, Yvan has played a pivotal role in the significant […]

We are very proud to announce that we have received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies. This makes us the first CDMO in Canada to achieve this milestone.  The approval follows an inspection by the cell and gene therapy experts from Health Canada. The DEL […]

C3i is pleased to partner with Octane Orthobiologics Inc and Orthopaedic Innovation Center Inc with the support of NGen for automation and scale up the biomanufacturing of cartilage implants for commercial-level production. NGen has announced over $32.3 million in Global Innovation Cluster funding for 15 new advanced manufacturing projects. With industry contributions of $54.4 million, […]

The Montreal-based CDMO C3i Center Inc is paving the way in the cell and gene therapy industry in North American and Canada as one of a few contract development and manufacturing organizations (CDMOs) to be producing in North America and for Europe. “We are proud of our team has worked very hard to be able […]